Citations (80)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Julie-Anne Tanner, Lisa C Brown, Kunbo Yu, James Li & Bryan M Dechairo. (2019) Canadian Medication Cost Savings Associated with Combinatorial Pharmacogenomic Guidance for Psychiatric Medications. ClinicoEconomics and Outcomes Research 11, pages 779-787.
Read now
Read now
Chiara Fabbri, Ladislav Hosak, Rainald Mössner, Ina Giegling, Laura Mandelli, Frank Bellivier, Stephan Claes, David A. Collier, Alejo Corrales, Lynn E. Delisi, Carla Gallo, Michael Gill, James L. Kennedy, Marion Leboyer, Amanda Lisoway, Wolfgang Maier, Miguel Marquez, Isabelle Massat, Ole Mors, Pierandrea Muglia, Markus M. Nöthen, Michael C. O’Donovan, Jorge Ospina-Duque, Peter Propping, Yongyong Shi, David St Clair, Florence Thibaut, Sven Cichon, Julien Mendlewicz, Dan Rujescu & Alessandro Serretti. (2017) Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. The World Journal of Biological Psychiatry 18:1, pages 5-28.
Read now
Read now
Chiara Fabbri, Concetta Crisafulli, Marco Calabrò, Edoardo Spina & Alessandro Serretti. (2016) Progress and prospects in pharmacogenetics of antidepressant drugs. Expert Opinion on Drug Metabolism & Toxicology 12:10, pages 1157-1168.
Read now
Read now
Giovanna Gentile, Fabiola Cipolla, Matilde Capi, Maurizio Simmaco, Luana Lionetto & Marina Borro. (2016) Precise medical decision making in geriatric anti-depressant therapy. Expert Review of Precision Medicine and Drug Development 1:4, pages 387-396.
Read now
Read now
D. Brixner, E. Biltaji, A. Bress, S. Unni, X. Ye, T. Mamiya, K. Ashcraft & J. Biskupiak. (2016) The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. Journal of Medical Economics 19:3, pages 213-228.
Read now
Read now
Articles from other publishers (75)
John Young, Aileen Jimenez, Madeline Pruett, Laken Hancock & McCall Schruff. (2023) A randomized controlled trial of analogue pharmacogenomic testing feedback for psychotropic medications. PEC Innovation 2, pages 100119.
Crossref
Crossref
N. A. Shnayder, A. V. Kidyaeva, E. E. Vaiman, A. R. Asadullin, M. M. Petrova, D. S. Kaskaeva, G. V. Matyushin, A. A. Evsyukov, E. V. Galko, N. P. Garganeeva, G. A. Chumakova, N. V. Lareva, N. G. Neznanov & R. F. Nasyrova. (2023) Role of Pharmacokinetics and Pharmacogenetics of Antidepressant-Induced Prolongation of the QT Interval and Torsade de Pointes in Patients with Mental Disorders. Personalized Psychiatry and Neurology 3:2, pages 72-119.
Crossref
Crossref
A.G. Mohiuddin, J. Howie, D Herbert, C.A. Bousman & J.L. Kennedy. (2023) Pharmacogenetic testing utility in psychiatry: A case report of serotonin syndrome. Psychiatry Research Case Reports 2:1, pages 100128.
Crossref
Crossref
Octavian Vasiliu. (2023) The pharmacogenetics of the new-generation antipsychotics – A scoping review focused on patients with severe psychiatric disorders. Frontiers in Psychiatry 14.
Crossref
Crossref
Sandosh Padmanabhan, Clea du Toit & Anna F. Dominiczak. (2023) Cardiovascular precision medicine – A pharmacogenomic perspective. Cambridge Prisms: Precision Medicine 1.
Crossref
Crossref
Joseph P. Jarvis, Scott E. Megill, Peter Silvester & Jeffrey A. Shaman. (2022) Maturing pharmacogenomic factors deliver improvements and cost efficiencies. Cambridge Prisms: Precision Medicine 1.
Crossref
Crossref
J. Kevin Hicks. 2023. Chronic Illness Care. Chronic Illness Care
3
17
.
Pratyusha Attaluri, Ayeshah G. Mohiuddin, Kowsar Teymouri & James L. Kennedy. 2020. Tasman’s Psychiatry. Tasman’s Psychiatry
1
17
.
Maria L. Ricardo-Silgado, Sneha Singh, Lizeth Cifuentes, Paul A. Decker, Daniel Gonzalez-Izundegui, Ann M. Moyer, Maria D. Hurtado, Michael Camilleri, Suzette J. Bielinski & Andres Acosta. (2022) Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study. BMC Medicine 20:1.
Crossref
Crossref
Murray Keogh, Maren S. Fragala, Arul Prakasam Peter, Raymond A. Lorenz, Steven E. Goldberg & Jeffrey A. Shaman. (2022) Early Insights From a Pharmacogenomic-Enriched Comprehensive Medication Management Program Implementation in an Adult Employee Population. Journal of Occupational & Environmental Medicine 64:12, pages e818-e822.
Crossref
Crossref
Maren S. FragalaJeffrey A. ShamanRaymond A. LorenzSteven E. Goldberg. (2022) Role of Pharmacogenomics in Comprehensive Medication Management: Considerations for Employers. Population Health Management 25:6, pages 753-762.
Crossref
Crossref
Cathelijne H. van der Wouden, Henk-Jan Guchelaar & Jesse J. Swen. (2022) Precision Medicine Using Pharmacogenomic Panel-Testing. Clinics in Laboratory Medicine 42:4, pages 587-602.
Crossref
Crossref
Nicholette T. Sloat, Beverly M. Yashar, Vicki L. Ellingrod & Kristen M. Ward. (2022) Assessing the impact of pre‐test education on patient knowledge, perceptions, and expectations of pharmacogenomic testing to guide antidepressant use. Journal of Genetic Counseling 31:6, pages 1373-1382.
Crossref
Crossref
Sarah A. Morris, Ashraf T. Alsaidi, Allison Verbyla, Adilen Cruz, Casey Macfarlane, Joseph Bauer & Jai N. Patel. (2022)
Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (
CPIC
) Guidelines: A Systematic Review
. Clinical Pharmacology & Therapeutics 112:6, pages 1318-1328.
Crossref
Crossref
Justo Pinzón-Espinosa, Marte van der Horst, Janneke Zinkstok, Jehannine Austin, Cora Aalfs, Albert Batalla, Patrick Sullivan, Jacob Vorstman & Jurjen J. Luykx. (2022) Barriers to genetic testing in clinical psychiatry and ways to overcome them: from clinicians’ attitudes to sociocultural differences between patients across the globe. Translational Psychiatry 12:1.
Crossref
Crossref
Evangelia Eirini Tsermpini, Zeina N. Al-Mahayri, Bassam R. Ali & George P. Patrinos. (2021) Clinical implementation of drug metabolizing gene-based therapeutic interventions worldwide. Human Genetics 141:6, pages 1137-1157.
Crossref
Crossref
Maria J. Arranz, Juliana Salazar, Valentin Bote, Alicia Artigas-Baleri, Alexandre Serra-LLovich, Emma Triviño, Jordi Roige, Carlos Lombardia, Martha Cancino, Marta Hernandez, Marc Cendros, Enric Duran-Tauleria, Natalia Maraver & Amaia Hervas. (2022) Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers. Pharmaceutics 14:5, pages 999.
Crossref
Crossref
Lauren Roscizewski, Amy Henneman & Tara Snyder. (2022) Effect of pharmacogenomic testing on pharmacotherapy decision making in patients with symptoms of depression in an interprofessional primary care clinic. Journal of the American Pharmacists Association 62:2, pages 569-574.e1.
Crossref
Crossref
Antonio Del Casale, Leda Marina Pomes, Luca Bonanni, Federica Fiaschè, Clarissa Zocchi, Alessio Padovano, Ottavia De Luca, Gloria Angeletti, Roberto Brugnoli, Paolo Girardi, Robert Preissner, Marina Borro, Giovanna Gentile, Maurizio Pompili & Maurizio Simmaco. (2022) Pharmacogenomics-Guided Pharmacotherapy in Patients with Major Depressive Disorder or Bipolar Disorder Affected by Treatment-Resistant Depressive Episodes: A Long-Term Follow-Up Study. Journal of Personalized Medicine 12:2, pages 316.
Crossref
Crossref
Anjali Dagar, Suneela Cherlopalle, Veena Ahuja, Lillian Senko, Robert S. Butler, Joseph Austerman, Amit Anand & Tatiana Falcone. (2022) Real-world experience of using combinatorial pharmacogenomic test in children and adolescents with depression and anxiety. Journal of Psychiatric Research 146, pages 83-86.
Crossref
Crossref
James M. Stevenson, April Schultz, Amanda Massmann, Joel Van Heukelom & Casey Overby Taylor. 2022. Clinical Decision Support for Pharmacogenomic Precision Medicine. Clinical Decision Support for Pharmacogenomic Precision Medicine
175
200
.
Alan Talevi & Carolina L. Bellera. 2022. The ADME Encyclopedia. The ADME Encyclopedia
781
786
.
Catherine R. Virelli, Ayeshah G. Mohiuddin & James L. Kennedy. (2021) Barriers to clinical adoption of pharmacogenomic testing in psychiatry: a critical analysis. Translational Psychiatry 11:1.
Crossref
Crossref
Lisa Brown, James Li, Naryan Katel, Kunbo Yu, Evangelia Fatourou, Brett Himmler & Angelos Halaris. (2021) Pharmacogenetic Testing in an Academic Psychiatric Clinic: A Retrospective Chart Review. Journal of Personalized Medicine 11:9, pages 896.
Crossref
Crossref
Kariofyllis Karamperis, Maria Koromina, Panagiotis Papantoniou, Maria Skokou, Filippos Kanellakis, Konstantinos Mitropoulos, Athanassios Vozikis, Daniel J. Müller, George P. Patrinos & Christina Mitropoulou. (2021) Economic evaluation in psychiatric pharmacogenomics: a systematic review. The Pharmacogenomics Journal 21:4, pages 533-541.
Crossref
Crossref
Carin A. T. C. Lunenburg, Janne P. Thirstrup, Jonas Bybjerg-Grauholm, Marie Bækvad-Hansen, David M. Hougaard, Merete Nordentoft, Thomas Werge, Anders D. Børglum, Ole Mors, Preben B. Mortensen & Christiane Gasse. (2021) Pharmacogenetic genotype and phenotype frequencies in a large Danish population-based case-cohort sample. Translational Psychiatry 11:1.
Crossref
Crossref
Christine M. Ramsey, Kevin G. Lynch, Michael E. Thase, Joel Gelernter, Henry R. Kranzler, Jeffrey M. Pyne, Mei-Chiung Shih, Annjannette Stone & David W. Oslin. (2021) Prevalence of predicted gene-drug interactions for antidepressants in the treatment of major depressive disorder in the Precision Medicine in Mental Health Care Study. Journal of Affective Disorders 282, pages 1272-1277.
Crossref
Crossref
Angelos Halaris, Emilie Sohl & Elizabeth A. Whitham. (2021) Treatment-Resistant Depression Revisited: A Glimmer of Hope. Journal of Personalized Medicine 11:2, pages 155.
Crossref
Crossref
Alan Talevi & Carolina L. Bellera. 2021. The ADME Encyclopedia. The ADME Encyclopedia
1
5
.
Samantha Breaux, Francis Arthur Derek Desrosiers, Mauricio Neira, Sunita Sinha & Corey Nislow. (2020) Pharmacogenomics at the Point of Care: A Community Pharmacy Project in British Columbia. Journal of Personalized Medicine 11:1, pages 11.
Crossref
Crossref
Don Roosan, Angela Hwang, Anandi V Law, Jay Chok & Moom R Roosan. (2020) The inclusion of health data standards in the implementation of pharmacogenomics systems: a scoping review. Pharmacogenomics 21:16, pages 1191-1202.
Crossref
Crossref
Michael R. Jablonski, Raymond Lorenz, James Li & Bryan M. Dechairo. (2019) Economic Outcomes Following Combinatorial Pharmacogenomic Testing for Elderly Psychiatric Patients. Journal of Geriatric Psychiatry and Neurology 33:6, pages 324-332.
Crossref
Crossref
Cathelijne H. van der Wouden, Henk-Jan Guchelaar & Jesse J. Swen. (2020) Precision Medicine Using Pharmacogenomic Panel-Testing. Advances in Molecular Pathology 3, pages 131-142.
Crossref
Crossref
Kimberly M. Deininger, Shirley M. Tsunoda, Jan D. Hirsch, Heather Anderson, Yee Ming Lee, Colleen K. McIlvennan, Robert L. PageIIII, Jacinda N. Tran & Christina L. Aquilante. (2020) National survey of physicians’ perspectives on pharmacogenetic testing in solid organ transplantation. Clinical Transplantation 34:10.
Crossref
Crossref
Kevin T Bain, Calvin H Knowlton & Adriana Matos. (2020) Cost avoidance related to a pharmacist-led pharmacogenomics service for the Program of All-inclusive Care for the Elderly. Pharmacogenomics 21:10, pages 651-661.
Crossref
Crossref
Craig William Heise, Tyler Gallo, Steven C. Curry & Raymond L. Woosley. (2020) Identification of populations likely to benefit from pharmacogenomic testing. Pharmacogenetics and Genomics 30:5, pages 91-95.
Crossref
Crossref
Andrea R. Collins, Simon Kung, Jacqueline T. Ho, Jessica A. Wright, Kristina C. Dammen, Emily K. Johnson, Maria I. Lapid & Jonathan G. Leung. (2020) Pharmacogenetic testing in psychiatric inpatients with polypharmacy is associated with decreased medication side effects but not via medication changes. Journal of Psychiatric Research 126, pages 105-111.
Crossref
Crossref
Julie-Anne Tanner, Paige E Davies, Christopher C Overall, Daniel Grima, Julian Nam & Bryan M Dechairo. (2020) Cost–effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective. Pharmacogenomics 21:8, pages 521-531.
Crossref
Crossref
Lisa Brown, Oliver Vranjkovic, James Li, Kunbo Yu, Talal Al Habbab, Holly Johnson, Krystal Brown, Michael R Jablonski & Bryan Dechairo. (2020) The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis. Pharmacogenomics 21:8, pages 559-569.
Crossref
Crossref
Christopher D. King, Agustin G. Yip, Ying A. Cao, Fernando Rodriguez-Villa, David S. Krause, Daniel Dowd & Kerry J. Ressler. (2020) Open-label pilot study of psychiatric pharmacogenetic testing in an adult psychiatric inpatient population. Personalized Medicine in Psychiatry 21-22, pages 100060.
Crossref
Crossref
Virginia M. Conley, Sandra Daack-Hirsch, Katie Halbmaier & Lisa Shaw. (2019) Bringing Personalized Medicine to a PACT Program: A Quality Improvement Project. Journal of the American Psychiatric Nurses Association 26:1, pages 77-85.
Crossref
Crossref
Jonathan C.W. Liu, Ilona Gorbovskaya, Chad Bousman, Lisa C. Brown & Daniel J. Müller. 2020. Personalized Psychiatry. Personalized Psychiatry
449
457
.
Joanna M. Biernacka, Ahmed T. Ahmed, Balwinder Singh & Mark A. Frye. 2020. Personalized Psychiatry. Personalized Psychiatry
403
412
.
Kristi Krebs & Lili Milani. (2019) Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good. Human Genomics 13:1.
Crossref
Crossref
Cathelijne H. Wouden, Mandy H. van Rhenen, Wafa O.M. Jama, Magnus Ingelman‐Sundberg, Volker M. Lauschke, Lidija Konta, Matthias Schwab, Jesse J. Swen & Henk‐Jan Guchelaar. (2019)
Development of the
PG
x‐Passport: A Panel of Actionable Germline Genetic Variants for Pre‐Emptive Pharmacogenetic Testing
. Clinical Pharmacology & Therapeutics 106:4, pages 866-873.
Crossref
Crossref
Maria J. Arranz, Alex Gonzalez-Rodriguez, Josefina Perez-Blanco, Rafael Penadés, Blanca Gutierrez, Laura Ibañez, Barbara Arias, Mercè Brunet, Jorge Cervilla, Juliana Salazar & Rosa Catalan. (2019) A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments. Translational Psychiatry 9:1.
Crossref
Crossref
John F. Greden, Sagar V. Parikh, Anthony J. Rothschild, Michael E. Thase, Boadie W. Dunlop, Charles DeBattista, Charles R. Conway, Brent P. Forester, Francis M. Mondimore, Richard C. Shelton, Matthew Macaluso, James Li, Krystal Brown, Alexa Gilbert, Lindsey Burns, Michael R. Jablonski & Bryan Dechairo. (2019) Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapies. Journal of Psychiatric Research 114, pages 211-213.
Crossref
Crossref
Camilla Callegari, Celeste Isella, Ivano Caselli, Nicola Poloni & Marta Ielmini. (2019) Pharmacogenetic Tests in Reducing Accesses to Emergency Services and Days of Hospitalization in Bipolar Disorder: A 2-Year Mirror Analysis. Journal of Personalized Medicine 9:2, pages 22.
Crossref
Crossref
John F. Greden, Sagar V. Parikh, Anthony J. Rothschild, Michael E. Thase, Boadie W. Dunlop, Charles DeBattista, Charles R. Conway, Brent P. Forester, Francis M. Mondimore, Richard C. Shelton, Matthew Macaluso, James Li, Krystal Brown, Alexa Gilbert, Lindsey Burns, Michael R. Jablonski & Bryan Dechairo. (2019) Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. Journal of Psychiatric Research 111, pages 59-67.
Crossref
Crossref
Y. W. Francis Lam. 2019. Pharmacogenomics. Pharmacogenomics
385
394
.
Y. W. Francis Lam & Toshiyuki Someya. 2019. Pharmacogenomics. Pharmacogenomics
181
225
.
Changsu Han, Sheng-Min Wang, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand, Laura Mandelli, Chi-Un Pae & Alessandro Serretti. (2018) A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. Clinical Psychopharmacology and Neuroscience 16:4, pages 469-480.
Crossref
Crossref
Joachim Benitez, Christina L Cool & Dennis J Scotti. (2018) Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders. Personalized Medicine 15:6, pages 481-494.
Crossref
Crossref
Chad A. Bousman & Boadie W. Dunlop. (2018) Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. The Pharmacogenomics Journal 18:5, pages 613-622.
Crossref
Crossref
Julie-Anne Tanner, Paige E. Davies, Nicholas C. Voudouris, Anashe Shahmirian, Deanna Herbert, Nicole Braganza, Ana Gugila, Bryan M. Dechairo & James L. Kennedy. (2018) Combinatorial pharmacogenomics and improved patient outcomes in depression: Treatment by primary care physicians or psychiatrists. Journal of Psychiatric Research 104, pages 157-162.
Crossref
Crossref
Erik J. GroesslSteven R. TallyNaomi HilleryAlejandra MacielJorge A. Garces. (2018) Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder. Journal of Managed Care & Specialty Pharmacy 24:8, pages 726-734.
Crossref
Crossref
Chiara Fabbri, Joseph Zohar & Alessandro Serretti. (2018) Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials. Progress in Neuro-Psychopharmacology and Biological Psychiatry 86, pages 36-44.
Crossref
Crossref
Michael R Jablonski, Nina King, Yongbao Wang, Joel G Winner, Lucas R Watterson, Sandra Gunselman & Bryan M Dechairo. (2018) Analytical validation of a psychiatric pharmacogenomic test. Personalized Medicine 15:3, pages 189-197.
Crossref
Crossref
D. J. Müller, E. J. Brandl, F. Degenhardt, K. Domschke, H. Grabe, O. Gruber, J. Hebebrand, W. Maier, A. Menke, M. Riemenschneider, M. Rietschel, D. Rujescu, T. G. Schulze, L. Tebartz van Elst, O. Tüscher & J. Deckert. (2018) Pharmakogenetik in der Psychiatrie: eine StandortbestimmungPharmacogenetics in psychiatry: state of the art. Der Nervenarzt 89:3, pages 290-299.
Crossref
Crossref
Deanna Herbert, Maria Neves-Pereira, Ruth Baidya, Sheraz Cheema, Sarah Groleau, Anashe Shahmirian, Arun K. Tiwari, Clement C. Zai, Nicole King, Daniel J. Müller & James L. Kennedy. (2018) Genetic testing as a supporting tool in prescribing psychiatric medication: Design and protocol of the IMPACT study. Journal of Psychiatric Research 96, pages 265-272.
Crossref
Crossref
Hayley P. Drozd, Sotirios F. Karathanasis, Andrei I. Molosh, Jodi L. Lukkes, D. Wade Clapp & Anantha Shekhar. 2018. Genetic Models and Molecular Pathways Underlying Autism Spectrum Disorders. Genetic Models and Molecular Pathways Underlying Autism Spectrum Disorders
113
158
.
Chiara Fabbri & Alessandro Serretti. 2018. Understanding Depression. Understanding Depression
3
16
.
J. Kevin Hicks & Henry M. Dunnenberger. 2018. Chronic Illness Care. Chronic Illness Care
3
16
.
Elizabeth Le, Sowmya Iyer, Teja Patil, Ron Li, Jonathan H. Chen, Michael Wang & Erica Sobel. 2018. Guide to Big Data Applications. Guide to Big Data Applications
415
448
.
Célia Lloret-Linares, Youssef Daali, Sylvie Chevret, Isabelle Nieto, Fanny Molière, Philippe Courtet, Florence Galtier, Raphaëlle-Marie Richieri, Sophie Morange, Pierre-Michel Llorca, Wissam El-Hage, Thomas Desmidt, Frédéric Haesebaert, Philippe Vignaud, Jerôme Holtzmann, Jean-Luc Cracowski, Marion Leboyer, Antoine Yrondi, Fabienne Calvas, Liova Yon, Philippe Le Corvoisier, Olivier Doumy, Kyle Heron, Damien Montange, Siamak Davani, Julien Déglon, Marie Besson, Jules Desmeules, Emmanuel Haffen & Frank Bellivier. (2017) Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study). BMC Pharmacology and Toxicology 18:1.
Crossref
Crossref
Chad A. Bousman, Malcolm Forbes, Mahesh Jayaram, Harris Eyre, Charles F. Reynolds, Michael Berk, Malcolm Hopwood & Chee Ng. (2017) Antidepressant prescribing in the precision medicine era: a prescriber’s primer on pharmacogenetic tools. BMC Psychiatry 17:1.
Crossref
Crossref
Farrokh Alemi, Aryan Mazloum-Yazdi & Lora Peppard. (2017) Citalopram is less effective for patients with neurological disorder and/or post-traumatic stress disorder. Personalized Medicine in Psychiatry 4-6, pages 32-38.
Crossref
Crossref
Kimberly Peterson, Eric Dieperink, Johanna Anderson, Erin Boundy, Lauren Ferguson & Mark Helfand. (2017) Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder. Psychopharmacology 234:11, pages 1649-1661.
Crossref
Crossref
Kristen K Reynolds, Deanne L Pierce, Frederick Weitendorf & Mark W Linder. (2017) Avoidable drug–gene conflicts and polypharmacy interactions in patients participating in a personalized medicine program. Personalized Medicine 14:3, pages 221-233.
Crossref
Crossref
Lisa C. Brown, Raymond A. Lorenz, James Li & Bryan M. Dechairo. (2017) Economic Utility: Combinatorial Pharmacogenomics and Medication Cost Savings for Mental Health Care in a Primary Care Setting. Clinical Therapeutics 39:3, pages 592-602.e1.
Crossref
Crossref
J. Kevin Hicks & Howard L. McLeod. 2017. Genomic and Precision Medicine. Genomic and Precision Medicine
89
107
.
Natasa Bogavac-Stanojevic & Dragana Lakic. (2016) Biomarkers for Major Depressive Disorder: Economic Considerations. Drug Development Research 77:7, pages 374-378.
Crossref
Crossref
Kristen K. Reynolds, Beth A. McNally & Mark W. Linder. (2016) Clinical Utility and Economic Impact of CYP2D6 Genotyping. Clinics in Laboratory Medicine 36:3, pages 525-542.
Crossref
Crossref
Chad A Bousman & Malcolm Hopwood. (2016) Commercial pharmacogenetic-based decision-support tools in psychiatry. The Lancet Psychiatry 3:6, pages 585-590.
Crossref
Crossref
Alessandro Serretti & Janusz K. Rybakowski. 2016. Genetic Influences on Response to Drug Treatment for Major Psychiatric Disorders. Genetic Influences on Response to Drug Treatment for Major Psychiatric Disorders
111
117
.